Doses above 1.0mg cause spillover binding to MC3R and MC4R receptors, triggering nausea, spontaneous erections in males, and darkening of existing nevi
There is a class of drugs that lead to weight loss, glucagon-like peptide 1 (GLP-1) agonists and the total GLP-1 market (includes peptides, orals and injectables), is estimated to be worth ~$37 billion in 2023, with projected growth to $138 billion by 2031
As traditional lifestyle and behavioral interventions often yield variable outcomes, and with rising projections of childhood obesity, pharmacological treatment options like GLP-1 RAs are becoming increasingly relevant
So, you may be wondering how to know when its time for IV drips
The required information typically includes: Diagnosis: Documentation of the patients condition, such as type 2 diabetes, obesity, hypertension, or cardiovascular issues, that warrants the use of a GLP-1 medication
They did not directly measure GLP-1 or test whether people eat less or lose weight